晚期卵巢癌新辅助化疗的疗效分析

[目的]观察新辅助化疗治疗晚期卵巢癌的疗效和毒副反应。[方法]治疗组37例患者采用新辅助化疗,对照组30例病人不进行新辅助化疗。治疗组患者新辅助化疗1～3个周期后行卵巢癌减瘤术。对照组患者经术前准备后直接进行手术。术后化疗方案两组相同。通过观察疗效、毒副反应、手术时间、术中出血、手术残留、手术并发症等,评价新辅助化疗在卵巢癌治疗中的作用及安全性。[结果]新辅助化疗组的总有效率为91.9(34/37);胸、腹水控制率为94.6(35/37);患者新辅助化疗后Kamofsky评分均有明显提高,毒副反应可耐受。化疗后均进行了广泛性全子宫、双附件、大网膜、阑尾及受累脏器切除术和淋巴清扫术。对照组总有效率为76.7(23/31);胸、腹水控制率为83.3(35/37);患者治疗后Kamofsky评分均有提高,毒副反应可耐受。两组近期疗效比较及胸腹水控制率比较差异均有统计学意义(P=0.040;P=0.037);两组满意肿瘤细胞减灭术比较差异有统计学意义(P=0.01);两组胃肠道反应和骨髓抑制情况不良反应比较差异无统计学意义(P=0.897;P=0.911)。[结论]卵巢癌新辅助化疗是安全有效的,毒副作用轻微。

A CLINICAL STUDY ON ADVANCED OVARIAN CANCER BY NEOADJUVANT CHEMOTHERAPY

[Objective]To study the clinical effect of neoadjuvant chemotherapy(NACT)in advanced ovarian cancer.[Methods]67 patients with advanced ovarian cancer were divided into two groups.In treatment group,37 patients were received 1-3 courses of intravenous chemotherapy before resection of ovarian cancer.In control group,30 patients were operated directly.All the patients in both groups received same chemotherapy regimens after operation.Observed efficacy,side effects of chemotherapy,operation time,blood loss,surg...